Last reviewed · How we verify
CKD-828(placebo)
CKD-828 is a placebo control used in clinical trials and has no active pharmacological mechanism.
At a glance
| Generic name | CKD-828(placebo) |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation, CKD-828(placebo) contains no active pharmaceutical ingredient and serves as a control comparator in phase 3 clinical trials. It is used to establish the efficacy and safety profile of the active drug candidate through blinded comparison. Placebo responses help distinguish true drug effects from natural disease progression and observer bias.
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (PHASE3)
- Efficacy and Safety of TELMINUVO to Stage 2 Hypertension (PHASE3)
- Efficacy and Safety of CKD-828 to Stage 2 Hypertension (PHASE3)
- CKD-828 Primary Hypertension Trial(Dose-selection) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-828(placebo) CI brief — competitive landscape report
- CKD-828(placebo) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI